Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Mediwound (MDWD)
NASDAQ:MDWD
MDWD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$12.78 - $24.00
Previous CloseN/A
Volume29.05K
Average Volume (3M)71.77K
Market Cap
$200.74M
Enterprise Value$151.46M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.29
Next Earnings
Mar 13, 2025EPS Estimate
-0.61Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.90
Shares Outstanding10,786,423
10 Day Avg. Volume45,608
30 Day Avg. Volume71,769
Standard Deviation0.17
R-Squared0.06
Alpha0.00384
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)10.75
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market Cap0.75
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit42.33
Enterprise Value/Ebitda-11.23
Forecast
1Y Price Target
$26.67Price Target Upside50.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
---
Mediwound News
PremiumCompany Announcements
MediWound Launches Phase III Trial for EscharEx Targeting Venous Leg Ulcers
PremiumCompany Announcements
Mediwound Advances in Enzymatic Therapeutics with Strategic Expansions
PremiumCompany Announcements
MediWound Approves 2024 Share Incentive Plan to Boost Employee Engagement
PremiumCompany Announcements
MediWound Advances Enzymatic Therapeutics Amid Financial Shifts---
Bulls Say, Bears Say
Bulls Say
Analyst RecommendationAnalyst recommends buying MediWound Ltd. stock.
Market ExpansionNexoBrid is expanding into new markets including the US, Japan, and India, and has secured a partnership for promotion in European countries.
Product PotentialEscharEx is being developed for enzymatic debridement of chronic wounds in the outpatient setting, representing a potential ~$2B market opportunity.
Bears Say
Revenue DeclineMediWound reported a decline of 14% sequentially in revenues due to reduced development support from BARDA.
Revenue GuidanceMediWound lowered revenue guidance for 2024 to 2026 due to uncertainty surrounding BARDA funding and its impact on development support.
Risks And ChallengesThe stock rating acknowledges risks including clinical, regulatory, commercial, collaboration, financial, and intellectual property challenges.
---
Ownership Overview
―
Insiders
1.89% Mutual Funds
28.39% Other Institutional Investors
65.36% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
MDWD FAQ
What was Mediwound’s price range in the past 12 months?
Mediwound lowest stock price was $12.78 and its highest was $24.00 in the past 12 months.
What is Mediwound’s market cap?
Mediwound’s market cap is $200.74M.
When is Mediwound’s upcoming earnings report date?
Mediwound’s upcoming earnings report date is Mar 13, 2025 which is in 19 days.
How were Mediwound’s earnings last quarter?
Mediwound released its earnings results on Nov 26, 2024. The company reported -$0.98 earnings per share for the quarter, missing the consensus estimate of -$0.477 by -$0.503.
Is Mediwound overvalued?
According to Wall Street analysts Mediwound’s price is currently Undervalued.
Does Mediwound pay dividends?
Mediwound does not currently pay dividends.
What is Mediwound’s EPS estimate?
Mediwound’s EPS estimate is -0.61.
How many shares outstanding does Mediwound have?
Mediwound has 10,786,423 shares outstanding.
What happened to Mediwound’s price movement after its last earnings report?
Mediwound reported an EPS of -$0.98 in its last earnings report, missing expectations of -$0.477. Following the earnings report the stock price went down -2.481%.
Which hedge fund is a major shareholder of Mediwound?
Currently, no hedge funds are holding shares in MDWD
---
Mediwound Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$26.67 (50.85% Upside)
$26.67 (50.85% Upside)
Blogger Sentiment
Bullish
MDWD Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 252.0 Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 1.0%
Last 30 Days ▼ 6.4%
Last 30 Days ▼ 6.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
33.43%
12-Months-Change
Fundamentals
Return on Equity
-83.40%
Trailing 12-Months
Asset Growth
11.51%
Trailing 12-Months
Company Description
Mediwound
MediWound Ltd. is a biopharmaceutical company engaging in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. Its product is NexoBrid. The company was founded by Lior Rosenberg and Marian Gorecki in 2001 and is headquartered in Yavne, Israel.
---
MDWD Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant achievements including FDA approval for NexoBrid's pediatric use, strategic funding, and progress with EscharEx. However, financial challenges such as revenue decline, operating losses, and adjusted guidance were noted. While the company's strategic advancements are promising, financial metrics indicate areas for improvement.Read More>---
MDWD Stock 12 Month Forecast
Average Price Target
$26.67
▲(50.85% Upside)
Technical Analysis
Cara Therapeutics
―
Aclaris Therapeutics
―
Arcus Biosciences
―
Verrica Pharmaceuticals
―
Best Analysts Covering MDWD
1 Year
1 Year Success Rate
13/17 ratings generated profit
1 Year Average Return
+40.48%
assigned a buy rating last month
Copying Michael Okunewitch's trades and holding each position for 1 Year would result in 76.47% of your transactions generating a profit, with an average return of +40.48% per trade.
---